Potential role of biventricular pacing beyond advanced systolic heart failure

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Cardiac resynchronization therapy (CRT) is established for advanced heart failure (HF).
• Current guidelines define CRT indications based on ejection fraction (EF), NYHA class, and QRS duration/morphology.
• Potential benefits may exist for patients outside these strict criteria.

Purpose of the Study:

• To review the role of CRT in specific patient subgroups not fully covered by current guidelines.
• To explore the potential for CRT to benefit patients with mild-to-moderate HF, those on right ventricular pacing, bradycardia patients, and those with congenital heart disease or specific cardiomyopathies.
• To highlight the need for further clinical trials to validate CRT's efficacy in these additional populations.

Main Methods:

• Literature review of existing studies and guidelines on CRT.
• Analysis of CRT's application in diverse HF patient subgroups.
• Synthesis of evidence regarding potential benefits and areas for future research.

Main Results:

• Established CRT indications include chronic HF patients (NYHA III-IV, EF ≤35%, prolonged QRS with LBBB or QRS ≥150 ms) and select NYHA II patients (EF ≤30%, QRS ≥130 ms with LBBB or QRS ≥150 ms).
• CRT may offer benefits in subgroups such as mild-to-moderate HF, patients transitioning from right ventricular pacing, bradycardia patients requiring pacing, and those with congenital heart disease or specific cardiomyopathies.
• Evidence for CRT efficacy in these subgroups is still emerging, necessitating further investigation.

Conclusions:

• CRT is effective for guideline-adherent advanced HF patients.
• Further research and clinical trials are essential to determine the expanded role and benefits of CRT in various HF subgroups.
• Optimizing CRT utilization may improve outcomes for a wider range of heart failure patients.